Abstract
The discovery of autoantibodies against M-type phospholipase A2 receptor (PLA2R1)1 as the main cause of membranous nephropathy (MN) has revolutionized diagnosis, prognostication, and treatment approaches in patients with MN.2 Different assays have been established for the detection of circulating PLA2R1 antibodies.2 Although Western blot is more sensitive, enzyme-linked immunosorbent assay (ELISA) and the indirect immunofluorescence test (IIFT) are commercially widely available and routinely used for the diagnosis and to make treatment decisions in patients with MN.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
